An in vitro model to compare the antimicrobial activity of silver-coated versus rifampicin-soaked vascular grafts

Annals of Vascular Surgery
S HardmanP Hayes

Abstract

In situ replacement of infected vascular grafts is an accepted alternative to total graft excision and extraanatomic replacement. Its success relies upon the ability of the newly inserted graft to resist recurrent infection. This study compares the efficacy of two methods used to reduce the risk of graft reinfection: rifampicin soaking versus silver bonding of grafts. The grafts' resistance to infection was tested in vitro in two protocols, each using a panel of seven common bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The length of time the grafts remained free of organisms was compared between the groups. Both the silver graft and the rifampicin-soaked graft were significantly better than control graft at preventing bacterial growth on the graft surface. The rifampicin inhibited the growth of the gram-positive organisms, including MRSA, significantly better than the silver graft on days 2 and 3 (p < 0.001). Conversely, the silver graft was significantly more effective against the gram-negative organisms until day 4 (p < 0.0001). Both types of graft inhibit the in vitro growth of bacteria more effectively than controls, with rifampicin being most effective against gram-positive organisms and silver b...Continue Reading

References

Dec 1, 1991·European Journal of Vascular Surgery·C J StrachanT R Ashton
Sep 1, 1987·Journal of Vascular Surgery·W H EdwardsJ L Mulherin
Feb 19, 1998·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·G Torsello, W Sandmann
Dec 30, 1998·The Journal of Hospital Infection·J M SchierholzG Pulverer
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R O Darouiche
May 22, 2001·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·A R NaylorS Darke

❮ Previous
Next ❯

Citations

May 22, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Laura K Braydich-StolleMarie-Claude Hofmann
Jan 9, 2010·International Journal of Molecular Sciences·Anna V PiterinaTim M McGloughlin
Jan 11, 2012·Seminars in Vascular Surgery·Jean-Baptiste Ricco, Ojan Assadian
Sep 11, 2010·The Journal of Surgical Research·Christian KuehnAxel Haverich
Mar 24, 2009·Birth Defects Research. Part C, Embryo Today : Reviews·Benjamin LucasMarie-Claude Hofmann
Aug 4, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Amanda M SchrandAli F Syed
Aug 8, 2006·Journal of Vascular Surgery·Jean-Baptiste Ricco, UNKNOWN InterGard Silver Study Group
Oct 2, 2007·Journal of Vascular Surgery·Isabelle JaverliatJean-Louis Gaillard
Mar 17, 2012·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·H GaoJ S Lindholt
Sep 10, 2013·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·P BergerF L Moll
Oct 10, 2009·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M Osińska-JaroszukA Uryniak
Jan 12, 2010·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·H GaoJ S Lindholt
Aug 28, 2007·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·H GaoJ S Lindholt
Jun 5, 2012·Vascular·Michel BattUNKNOWN Association Universitaire de Recherche en Chirurgie Vasculaire (AURC)
Sep 27, 2018·Nanomaterials·Francesca Gatto, Giuseppe Bardi
Jan 18, 2020·Biomolecules·Katarzyna SzałapataAnna Jarosz-Wilkołazka
Dec 9, 2009·Nano Letters·Krasimir VasilevHans J Griesser
May 22, 2021·Journal of Vascular Surgery·Hozan MuftyInge Fourneau

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery
M D'AddatoG Biasi
Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery
J J Earnshaw
© 2021 Meta ULC. All rights reserved